Received a response from AOR, here it is:
Thank you for your email. The dosage of Niacin used in Ortho Core maybe above the RDA but it is important to consider that the RDA is the dosage of Niacin that is thought to be optimal for the general population. It is generally calculated by increasing the AI by 20% and is not based on any clinical findings. The UL in Canada is 500 mg. In the EU where Niacin is used as a pharmaceutical the UL is set much lower. In clinical trials dosages of Niacin ranges between 100mg and over 2000 mg. The inositol hexanicotinate has been used in trials for peripheral vascular disease in dosages of 4000 mg without adverse effects. We have no reason to believe that a dosage of 116 mg would be of concern. Inositol Hexanicotinate tends to be dosed differently than regular niacin as well due to a completely different bioavailability curve. Regular Niacin peaks in plasma concentration after 45 minutes and then decreases rapidly, while inositol hexanicotinate takes up to 10 hours to reach a peak concentration. As Inositol Hexanicotinate is hydrolyzed in the blood stream so slowly, higher doses are required.
There were two reasons Niacin Hexanicotinate was chosen as the form of Niacin to be used by AOR. First, Flushing Niacin reduces compliance among the majority of consumers (some research has put this level at 39%). Most people do not have the patience to continue to use the product until the body becomes used to the flushing effect. We decided against using flushing niacin as it would not be used by a large portion of the population. We could have provided the flushing niacin in a lower dosage, however that would put our dosing below what is considered a therapeutic level, which we feel would significantly reduce the effectiveness of the product. Especially for those concerned with low energy levels. Secondly the forms of non-flushing Niacin currently available carry considerable risk for a percentage of the population. Niacinamide is the most common for used and it is not true niacin but a metabolite of niacin. Some studies have shown up to 52% of those who use Niacinamide over a long term basis develop liver damage. Inositol Hexanicotinate on the other hand has been used at dosages of 4000 mg daily for 4 month stretches has not shown any evidence of liver toxicity or even an increase in liver enzymes.
The evidence for Inositol Hexanicotinate is strongest for those suffering from peripheral vascular disease is stronger than the evidence for lowering blood lipids is true. We agree there needs to be more research done using Inositol Hexanicotinate as a standalone treatment for hyperlipidemia. However with similar pharmacokinetics as regular niacin and a history of clinical use in Europe for hyperlipidemia we believe we have made the right choice on our selection of Niacin. If one is looking to utilize Inositol Hexanicotinate for lowering blood lipids they will be taking a much higher dosage than what is provided in the Ortho Core and should be under the care of a qualified health care practitioner who can monitor their progress and adjust the dosage as needed.
Please let me know if you have any further questions.
Thank you and have a great day,
Katie Lemmon, RHN
Internal Sales and Marketing Coordinator
Product Information and Technical Support
Advanced Orthomolecular Research
Tel: 403-250-9997 or 800-387-0177, ext. 1820
Fax: 403-250-9974 or 877-219-9974